Toda S, Kotake C, Tsuno T, Narita Y, Yamasaki T, Konishi M
Bristol-Myers Squibb Research Institute, Tokyo, Japan.
J Antibiot (Tokyo). 1992 Oct;45(10):1580-6. doi: 10.7164/antibiotics.45.1580.
The structures of eurystatins A and B, new prolyl endopeptidase inhibitors, have been elucidated by chemical degradation and spectral studies. They have in common a unique 13-membered cyclic peptide core composed of L-leucine, L-ornithine and (S)-3-amino-2-oxobutyric acid, and differ from each other in the alpha,beta-unsaturated fatty acid attached to the alpha-amino moiety of the ornithine.
新型脯氨酰内肽酶抑制剂优司他汀A和B的结构已通过化学降解和光谱研究得以阐明。它们具有共同的由L-亮氨酸、L-鸟氨酸和(S)-3-氨基-2-氧代丁酸组成的独特的13元环肽核心,且彼此的区别在于连接在鸟氨酸α-氨基部分的α,β-不饱和脂肪酸。